Lactobacillus Reuteri grows in the Microalga Isochrysis Galbana Generating a Fermented Compound that reduces the AIEC Bacteria Harmfulness

E. Colantoni
Sapienza University of Rome

F. Palone
ENEA

V. Cesi
ENEA

B. Leter
ENEA

G. Sugoni
ENEA

I. Laudadio
Sapienza University of Rome

A. Negroni
ENEA

R. Vitali
ENEA

L. Stronati (laura.stronati@uniroma1.it)
Sapienza University of Rome

Research Article

Keywords: galbana, reuteri, aiec, obtained, cells, microalgae, omega3, probiotics

DOI: https://doi.org/10.21203/rs.3.rs-562224/v1

License: This work is licensed under a Creative Commons Attribution 4.0 International License.
Read Full License
Abstract

Microalgae are currently considered as alternative sustainable resources for high-value bioproducts such as omega3 polyunsaturated fatty acids (PUFAs). Probiotics are assumed to benefit human health by their direct actions on the composition and function of gut microbiota. Aims of the study are: 1) to set up the anaerobic growth of the probiotic *Lactobacillus reuteri* (*L. reuteri*) in the omega3-rich microalga *Isochrysis galbana* (*I. galbana*); 2) to assess the potential role of the obtained fermented compound (FC) to control the harmfulness of adherent invasive Escherichia coli (AIEC) to intestinal epithelial cells.

*I. galbana* powder solubilized in PBS was used for the anaerobic growth of *L. reuteri*. The lipidic content of *I. galbana* and FC was analyzed by GC-MS. Colorectal adenocarcinoma cells CACO2 and the AIEC strain LF82 were used for *in vitro* experiments.

*I. galbana* is shown to be an excellent culture medium for growing *L. reuteri*. The obtained FC significantly reduces the AIEC adhesiveness and invasiveness to intestinal epithelial cells.

We show for the first time that microalgae may represent an innovative culture medium to grow probiotics in anaerobiosis. The obtained FC shows beneficial properties for human health by controlling the harmfulness of AIEC bacteria.

Introduction

Among functional foods, microalgae are focusing the attention of the whole world thanks to their high content of elements of high value for the well-being of consumers, such as carotenoids, vitamins, essential amino acids, polyphenols and oils rich in omega [1–7]. Several studies have found that many of these components have an important impact on human health as they exhibit anti-mutagenic, anti-cancer, anti-oxidant and anti-inflammatory effects [8, 9]. Microalgae rich in polyunsaturated fatty acids (PUFA), in particular omega3-PUFA, which include eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), have aroused particular interest. Indeed, these bioactive compounds appear to be strategic for their effects on the cardiovascular system and for the prevention of cognitive disorders [10–14].

Microalgae species that produces high PUFA concentrations are *Nanochloropsis gaditana*, *Isochrysis galbana*, *Phaeodactylum tricornutum*, and *Cryptocodinium cohnii* [15]. In particular, *Isochrysis galbana* (*I. galbana*) can synthesize EPA and DHA and contains vitamins, polysaccharides, sterols and carotenoids which make it a valid source for human and animal nutrition [16–18]. Interestingly, several studies have also shown that *I. galbana* has beneficial effects on human health and could be thought as a nutraceutical as well as therapeutic agent for the management of inflammatory and oxidative damage-derived disorders [19–21].

Therapeutic microbiology is expanding and beneficial bacteria are being implemented as treatment and prevention strategies for immune disorders and infectious diseases. Currently, probiotics have become highly recognized as supplements for humans and animals due to their beneficial outcome on health
improvement and well-being maintenance [22–25]. *Lactobacillus reuteri* (*L. reuteri*), a commensal-derived anaerobic probiotic, that resides in the human gastrointestinal tract, shows many beneficial effects, such as prevention and/or amelioration of diverse disorders [26–29]. Recent evidence highlights the role of *L. reuteri* in controlling the growth and survival of pathobionts correlated with infectious or chronic gastrointestinal diseases, such as the adherent-invasive *Escherichia coli* (AIEC) [30, 31].

Here, we present an innovative and low-cost method for the growth of *L. reuteri* in raw seaweed extracts from *I. galbana* instead of the conventional medium, under conditions of oxygen deprivation (anaerobiosis). We demonstrate for the first time that *I. galbana* is an excellent culture medium for the growth of *L. reuteri*. Moreover, we show that the omega-3 present in the seaweed are still available after the fermentation process and the fermented compound (FC), obtained from the growth of *L. reuteri* in *I. galbana* in anaerobiosis and thus consisting of the probiotic in a medium with available microalgaereleased PUFA-omega3, slows the growth of AIEC bacteria and significantly limits their adhesiveness and invasiveness to intestinal epithelial cells.

**Materials And Methods**

**Microalgal and bacterial strains**

*I. galbana* lyophilized (Archimede Ricerche Srl, Camporosso, Imola, Italy) was solubilized in phosphate buffered saline (PBS) (36 mg/ml) and used for bacterial growth.

The adherent-invasive AIEC strain LF82 (kindly provided by Prof. Arlette Darfeuille-Michaud, Clermont Universite, Universite d’Auvergne, Clermont-Ferrand, France) was cultured in Tryptone Soy Agar (TSA; plates Oxoid, Basingstoke, UK) for 24 hours at 37°C and then sub-cultured in Tryptone Soy Broth (TSB; Oxoid, Basingstoke, UK) with overnight incubation at 150 rpm, 37°C.

Powder of *L. reuteri* DSM17398 (BioGaia, Stockholm, Sweden) was kept at -20°C, inoculated in commercial medium De Man, Rogosa and Sharpe (MRS; Sigma-Aldrich, St. Louis, USA) and incubated overnight, 37°C without agitation.

**Cell culture**

Human colorectal adenocarcinoma cell line, CACO2, was obtained from the American Type Culture Collection (ATCC, Rockville, MA, USA). Cells were grown at confluence at 37°C in Dulbecco’s minimum essential medium (DMEM; Gibco, Life Technologies, Carlsbad, CA, USA), supplemented with 10% inactivated fetal bovine serum (FBS; Euroclone, Milan, Italy) and 2 mM L-glutamine, 100 U/ml penicillin and 100 g/ml streptomycin (Biochrom, Berlin, Germany).

**Anaerobic growth of *L. reuteri***

For anaerobic growth, 2x10⁶ CFU/ml of *L. reuteri* were inoculated in MRS or in 5 ml of *I. galbana* solubilized in PBS (36 mg/ml). Each vial was capped and incubated anaerobically without agitation at
37°C for 120 hours (5 days).

The bacterial growth was evaluated at different times (24, 48, 72, 96, 120 hours) by plating serially diluted samples in PBS on MRS agar plates (1.2% agarose) and incubated at 37°C for 24 hours. Resulting colonies were counted and the viability (CFU/mL) value was calculated based on the plated dilution. After 5 days, the fermentation compound (FC) contained an average concentration of 3.5x10^7 CFU/ml.

Lipid extraction

Lipids were extracted from *I. galbana* (36 mg/ml) solubilized in PBS and FC of a single experiment and the analysis was performed in duplicate.

Samples were freeze-dried for 2 days at -40°C and 60 mBar pressure by freeze-dryer (Edwards). Each sample (5 mg) was resuspended with 1 ml of dichloromethane (DCM) and 0.5 ml of methanol/sulfuric acid (MeOH/ H₂SO₄) and sonicated for 1 hour at 50°C, 40 KHz frequency. Hexane (1 ml) was used as extracting solvent and, after agitation, calcium carbonate (16 mg) and H₂O (1 ml) were added and samples were centrifugated for 5 min at 2000 rpm. The separation of polar from apolar phase was repeated twice and finally the latter was dried with nitrogen flow (4 ml for each sample).

Gas-chromatography mass-spectrometry (GC-MS)

GC-MS analysis was performed by a 7890A gas chromatograph (Agilent) with capillary columns SBP-2331 (Sigma-Aldrich) [60 m, 0.25 mm inner diameter (ID), 0.2 µm film thickness]. Helium was used as carrier gas at a linear velocity of 36.26 cm/sec and 1µl of each sample was injected splitless. The initial column temperature was 40°C and held 4 min, ramped to 140°C at the rate of 20°C/min, ramped to 220°C at the rate of 2°C/min and held 1min and then finally increased to 260°C at the rate of 10°C/min and kept at this temperature for 5 min. The mass spectra were recorded using a 5975C mass spectrometer (Agilent) in full scan mode from 45-450 m/z and 240°C. The fatty acids concentration of each sample was determined using the software Xcalibur (Thermo Scientific, Waltham, USA) and 37 Component FAME Mix (Supelco, USA) was used as external standard for calibration.

AIEC adhesion and invasion assay

Adhesion assay

Caco2 cells were grown on 24-well plates at confluence (3x10⁵ cells) and infected with LF82 (3x10⁶ CFU), or LF82+ *L. reuteri* (3.5x10⁶ CFU), or LF82 + *I. galbana* (100µl), or LF82 + FC (100µl) at 37 °C for 3 hours. To quantify the adherence of LF82, we followed the protocol of A. Darfeuille-Michaud et al. [32]. Briefly, infected cells were washed twice in PBS and lysed for 10 minutes with 0.5 ml of 0.1% Triton X-100 in PBS buffer. Adherent bacteria were recovered and plated on LB agar plates. The latter were incubated at 37°C overnight and then the colonies were counted for statistical analysis.
**Invasion assay**

CACO2 cells were infected and incubated as above. For invasion assay, we followed the protocol of A. Darfeuille-Michaud et al [32]. Briefly, after incubation, cells were washed twice in sterile PBS and then incubated in DMEM and McCoy’s medium, respectively with 0.1 mg/ml gentamicin for 1 hour to kill the extracellular bacteria. Cells were washed twice in sterile PBS. Lysis, incubation and counts were performed as in the adhesion assay. To ensure maximum reproducibility, accuracy and statistical significance, adhesion and invasion assays were carried out simultaneously in triplicates. To obtain an accurate count of adhesive bacteria, the number of invasive colonies was subtracted from the number of the adhesive ones.

**Statistics**

Data are given as mean ± standard deviation. All experiments were repeated three times. Comparison between groups was performed by a two-tailed Student t-test (significance taken as $P<0.05$).

**Results**

The unicellular microalga *I. galbana* is an excellent culture medium for the growth of *L. reuteri*. *I. galbana* extracts were obtained from dehydrated whole seaweed. *L. reuteri* was inoculated at a concentration of $2 \times 10^6$ CFU/ml in physiological solution containing *I. galbana* (36 mg/ml) or commercial medium (MRS) and placed at 37°C. The growth was followed for 5 days, that is the time necessary for the bioavailable sugars to guarantee the growth of the lactobacillus in anaerobiosis. Results showed that *L. reuteri* grows in the microalga medium similarly as in MRS reaching the final concentration of $3.5 \times 10^7$ and $1.9 \times 10^7$, respectively (Fig. 1).

The PUFA-omega3 content of the microalgae *I. galbana* are still mostly available after the fermentation by *L. reuteri*. The GC-MS lipidomic analysis of *I. galbana* confirmed that the microalga is rich in omega3, especially DHA. More interestingly, the analysis showed that the availability of DHA and EPA is similar before and after fermentation by *L. reuteri*. Indeed, the amount of EPA is unchanged, while alpha-linoleic acid (ALA) and DHA undergoes a small variation between 15 and 20% less after fermentation (Fig. 2). Therefore, the FC, in its fullness, contains the probiotic but is also rich in omega3 and, thus, might represent a very innovative and beneficial compound for the human health.

*I. galbana* favors the growth of the probiotic *L. reuteri* respect to that of the pathobiont AIEC LF82

The AIEC bacteria, known as potent pro-inflammatory microorganisms, strongly increase in the gut of people with intestinal inflammatory disorders and represent a significant challenge for clinicians. Then, we investigated whether *I. galbana* could also represent an optimal culture medium for the growth of harmful bacteria. Then, *L. reuteri* and the AIEC prototype, LF82, were grown together in the microalgae.
Interestingly, although LF82 had been inoculated at a concentration of 1 log higher, in order to mimic the selective advantage this bacterial group has in the inflamed environment, however, the growth curve of LF82 decreases after the first 24 hours while that of *L. reuteri* improves and at the end of fermentation the two species are present at roughly the same concentration (9.9x10^6 and 6x10^6, respectively), clearly suggesting that the probiotic has an advantage in the microalgae culture medium (Fig. 3).

**The FC derived from the 5 days-growth of *L. reuteri* in *I. galbana* strongly limits the adhesiveness and invasiveness of LF82 to intestinal epithelial cells**

The human epithelial colorectal adenocarcinoma cells, CAC02, are a recognized *in vitro* model of intestinal epithelial barrier. Hence, we used confluent CAC02 cells to assess the ability of the FC, administered as such, to control the adhesiveness and invasiveness of AIEC LF82, better that the probiotic alone. Confluent CAC02 were exposed for 3 hours to LF82 alone (3x10^6 CFU) or LF82 + *L. reuteri* (3.5x10^6 CFU) or LF82 + *I. galbana* (100µl) or LF82 + FC (100µl).

Results showed that the FC significantly reduces the adhesion (P = 0.002) and invasion (P = 0.0002) of LF82 compared to the probiotic alone. Surprisingly, *I. galbana* shows a very good capacity to decrease AIEC harmfulness even if lower than that of the FC (Fig. 4).

**Discussion**

To date, probiotic production has almost exclusively been carried out using conventional batch fermentation and suspended cultures, but there is an emerging interest from the scientific community and increasing demand from the business world to explore and set up innovative fermentation technologies.

Here, we present a new method to grow the probiotic *L. reuteri* in the microalgae *I. galbana*, under anaerobiosis condition. The advantages of this protocol are several. First, the cost is low. Besides, the probiotic can be administered without being previously purified from its culture medium, which, on the contrary, being made up of an omega3-rich microalga, could show beneficial properties for the host organism. Finally, since probiotics must colonize an oxygen-deprived gut environment, the fermentation of the microalga in anaerobiosis can be considered a form of pre-adaptation of probiotics that could improve their survival in the bowel.

Interestingly, our results show for the first time that the microalgae *I. galbana* is an excellent medium to grow the probiotic *L. reuteri*, which in fact lives and proliferates in the microalgae as in the conventional medium.

Recent data demonstrate that adding the microalgae *Chlorella vulgaris* to the *Lactobacillus* spp. growth medium accelerates the growth and metabolic activity of bacteria, suggesting that the combination allows for the creation of innovative, functional products which confer favorable properties to the final product [33].
In addition to proposing the microalgae as a growth medium for Lactic acid bacteria, we also support the idea that the microalgae-probiotic combination shows great potential for generating a novel functional product. Actually, we show that, after fermentation, the PUFA-omega3, of which *Isochrysis* is rich, are not consumed by *L. reuteri*, who instead prefers the consumption of sugars, and remain almost all available in the FC, giving the latter beneficial properties.

Accordingly, we aimed to investigate whether the FC had the ability to impair AIEC-induced inflammation with greater effectiveness than the probiotic alone. AIEC bacteria represent a particular pathotype of *Escherichia coli* abnormally colonizing the intestinal mucosa of patients with chronic intestinal inflammation, such as those affected by Crohn’s disease [34]. Recent evidence suggests that perturbation of the microbial community (dysbiosis) favors the emergence of opportunistic pathogens, in particular AIEC, that can increase the incidence and severity of gut inflammation, since they strongly adhere to and invade intestinal epithelial cells, inducing inflammatory cytokine secretion [35]. Using an in vitro model of gut epithelial barrier, we first confirmed previous evidence that *L. reuteri* is able to reduce the pathogenicity of enteroinvasive *Escherichia coli* [36, 37], including AIEC [31]. More interestingly, we showed that the treatment with FC prevented the AIEC adhesiveness and invasiveness to epithelial cells more effectively than the probiotic alone. We speculate that this improved effect is due to the omega3 present in the compound that act in combination with the probiotic.

Furthermore, we showed for the first time that *I. galbana* itself significantly reduces the adhesiveness and invasiveness of AIEC LF82 to epithelial cells. Although previous authors demonstrated that several microalgae, including *I. galbana*, are prospective candidates to inhibit the growth of gram-positive bacteria [38], however, to our knowledge, their potential in controlling pathobionts has never been reported yet. It is worth noting that in our experimental set up, *I. galbana* had already proven to be a deterrent for the AIEC group, hampering their growth while favoring that of *L. reuteri*.

**Conclusions**

Current evidence indicates that microalgae have the potential to become a novel source of bioactive molecules, especially for those who might wish to enhance the nutritional and functional quality of foods. Even further, we show that microalgae may represent an innovative culture medium to grow probiotics in anaerobiosis and that the obtained FC should be administered as such without separating the probiotic from the culture medium which, indeed, by selecting a proper microalga, could be a useful resource of beneficial bioactive molecules such as omega3. Really, we demonstrate that the FC has beneficial properties by decreasing the harmfulness of AIEC bacteria to gut epithelial cells.

These findings are important in the development of novel tools for the production of probiotics, whose market is growing dynamically, as well as for the supply of novel fermented products that should represent in the future safe therapeutic agents to be utilized for the management of oxidative damage-derived or inflammatory disorders.
Finally, the *L. reuteri* grown in *I. galbana* should be considered a true novel vegetarian probiotic since free from all animal-derived ingredients differently from probiotics grown in the traditional culture medium.

**Declarations**

**Data Availability**

The data that support the findings of this study are available from the corresponding author [L. S.], upon reasonable request.

**Author contributions**

S.L. and C.V. conceived and designed the experiments; C.E., S.G. and L.B. conducted the experiments; L.I., V.R., N.A. and P.F. analyzed the data and performed the statistical analysis; S.L. wrote the manuscript. All authors read and approved the final manuscript.

**Additional information**

**Correspondence** and requests for materials should be addressed to S.L.

**References**

1. Pereira, A. G. *et al.* Xanthophylls from the Sea: Algae as Source of Bioactive Carotenoids. *Mar Drugs* **19**, (2021).
2. Barkia, I., Saari, N. & Manning, S. R. Microalgae for High-Value Products Towards Human Health and Nutrition. *Mar Drugs* **17**, (2019).
3. Galasso, C. *et al.* Microalgal Derivatives as Potential Nutraceutical and Food Supplements for Human Health: A Focus on Cancer Prevention and Interception. *Nutrients* **11**, (2019).
4. Giordano, M. & Wang, Q. Microalgae for Industrial Purposes. in *Biomass and Green Chemistry: Building a Renewable Pathway* (ed. Vaz Jr., S.) 133–167 (Springer International Publishing, 2018). doi:10.1007/978-3-319-66736-2_6.
5. Matos, J., Cardoso, C., Bandarra, N. M. & Afonso, C. Microalgae as healthy ingredients for functional food: a review. *Food Funct* **8**, 2672–2685 (2017).
6. Makri, A. *et al.* Lipid synthesized by micro-algae grown in laboratory- and industrial-scale bioreactors. *Engineering in Life Sciences* **11**, 52–58 (2011).
7. Raheem, A., Prinsen, P., Vuppaladadiyam, A. K., Zhao, M. & Luque, R. A review on sustainable microalgae based biofuel and bioenergy production: Recent developments. *Journal of Cleaner Production* **181**, 42–59 (2018).
8. Kiran, B. R. & Venkata Mohan, S. Microalgal Cell Biofactory-Therapeutic, Nutraceutical and Functional Food Applications. *Plants (Basel)* **10**, (2021).
9. Saide, A., Martínez, K. A., Ianora, A. & Lauritano, C. Unlocking the Health Potential of Microalgae as Sustainable Sources of Bioactive Compounds. *Int J Mol Sci* **22**, (2021).

10. Remize, M., Brunel, Y., Silva, J. L., Berthon, J.-Y. & Filaire, E. Microalgae n-3 PUFAs Production and Use in Food and Feed Industries. *Mar Drugs* **19**, (2021).

11. Chalima, A., Hatzidakis, A., Karnaouri, A. & Topakas, E. Integration of a dark fermentation effluent in a microalgal-based biorefinery for the production of high-added value omega-3 fatty acids. *Applied Energy* **241**, 130–138 (2019).

12. Aussant, J., Guihéneuf, F. & Stengel, D. B. Impact of temperature on fatty acid composition and nutritional value in eight species of microalgae. *Appl Microbiol Biotechnol* **102**, 5279–5297 (2018).

13. de Jesus Raposo, M. F., de Morais, R. M. S. C. & de Morais, A. M. M. B. Health applications of bioactive compounds from marine microalgae. *Life Sci* **93**, 479–486 (2013).

14. Peltomaa, E., Johnson, M. D. & Taipale, S. J. Marine Cryptophytes Are Great Sources of EPA and DHA. *Mar Drugs* **16**, (2017).

15. Santos-Sánchez, N. F. *et al.* Lipids rich in ω-3 polyunsaturated fatty acids from microalgae. *Appl Microbiol Biotechnol* **100**, 8667–8684 (2016).

16. Señoráns, M., Castejón, N. & Señoráns, F. J. Advanced Extraction of Lipids with DHA from Isochrysis galbana with Enzymatic Pre-Treatment Combined with Pressurized Liquids and Ultrasound Assisted Extractions. *Molecules* **25**, (2020).

17. Chacón-Lee, T. L. & González-Mariño, G. E. Microalgae for ‘Healthy’ Foods-Possibilities and Challenges. *Compr Rev Food Sci Food Saf* **9**, 655–675 (2010).

18. Gilbert-López, B. *et al.* Downstream processing of Isochrysis galbana: a step towards microalgal biorefinery. *Green Chem.* **17**, 4599–4609 (2015).

19. Matos, J. *et al.* Bioprospection of Isochrysis galbana and its potential as a nutraceutical. *Food Funct* **10**, 7333–7342 (2019).

20. Rodríguez-Luna, A. *et al.* Topical Application of Glycolipids from Isochrysis galbana Prevents Epidermal Hyperplasia in Mice. *Mar Drugs* **16**, (2017).

21. Sun, Y., Wang, H., Guo, G., Pu, Y. & Yan, B. The isolation and antioxidant activity of polysaccharides from the marine microalgae Isochrysis galbana. *Carbohydr Polym* **113**, 22–31 (2014).

22. Daliri, E. B.-M., Ofosu, F. K., Xiuqin, C., Chelliah, R. & Oh, D.-H. Probiotic Effector Compounds: Current Knowledge and Future Perspectives. *Front Microbiol* **12**, 655705 (2021).

23. Chang, C.-J. *et al.* Next generation probiotics in disease amelioration. *J Food Drug Anal* **27**, 615–622 (2019).

24. Sanders, M. E., Merenstein, D. J., Reid, G., Gibson, G. R. & Rastall, R. A. Probiotics and prebiotics in intestinal health and disease: from biology to the clinic. *Nat Rev Gastroenterol Hepatol* **16**, 605–616 (2019).

25. Zommiti, M., Chikindas, M. L. & Ferchichi, M. Probiotics-Live Biotherapeutics: a Story of Success, Limitations, and Future Prospects-Not Only for Humans. *Probiotics Antimicrob Proteins* **12**, 1266–
1289 (2020).
26. Athalye-Jape, G., Rao, S. & Patole, S. Lactobacillus reuteri DSM 17938 as a Probiotic for Preterm Neonates: A Strain-Specific Systematic Review. *JPEN J Parenter Enteral Nutr* **40**, 783–794 (2016).
27. Mangalat, N. *et al.* Safety and tolerability of Lactobacillus reuteri DSM 17938 and effects on biomarkers in healthy adults: results from a randomized masked trial. *PLoS One* **7**, e43910 (2012).
28. Mu, Q., Tavella, V. J. & Luo, X. M. Role of Lactobacillus reuteri in Human Health and Diseases. *Front Microbiol* **9**, 757 (2018).
29. Sung, V. *et al.* Lactobacillus reuteri to Treat Infant Colic: A Meta-analysis. *Pediatrics* **141**, (2018).
30. Costanzo, M. *et al.* Krill oil, vitamin D and Lactobacillus reuteri cooperate to reduce gut inflammation. *Benef Microbes* **9**, 389–399 (2018).
31. Van den Abbeele, P. *et al.* Arabinoxylans, inulin and Lactobacillus reuteri 1063 repress the adherent-invasive Escherichia coli from mucus in a mucosa-comprising gut model. *NPJ Biofilms Microbiomes* **2**, 16016 (2016).
32. Darfeuille-Michaud A. *et al.* High prevalence of adherent-invasive Escherichia coli associated with ileal mucosa in Crohn's disease. *Gastroenterology* **127**, 412–421 (2004).
33. Ścieszka, S. & Klewicka, E. Influence of the Microalga Chlorella vulgaris on the Growth and Metabolic Activity of Lactobacillus spp. Bacteria. *Foods* **9**, (2020).
34. Chervy, M., Barnich, N. & Denizot, J. Adherent-Invasive E. coli: Update on the Lifestyle of a Troublemaker in Crohn's Disease. *Int J Mol Sci* **21**, (2020).
35. Agus, A., Massier, S., Darfeuille-Michaud, A., Billard, E. & Barnich, N. Understanding Host-Adherent-Invasive Escherichia coli Interaction in Crohn's Disease: Opening Up New Therapeutic Strategies. *Biomed Res Int* 2014, (2014).
36. Bertin, Y. *et al.* Lactobacillus reuteri suppresses E. coli O157:H7 in bovine ruminal fluid: Toward a pre-slaughter strategy to improve food safety? *PLoS One* **12**, e0187229 (2017).
37. Wang, Y. *et al.* Probiotic potential of Lactobacillus on the intestinal microflora against Escherichia coli induced mice model through high-throughput sequencing. *Microb Pathog* **137**, 103760 (2019).
38. Alsenani, F. *et al.* Evaluation of microalgae and cyanobacteria as potential sources of antimicrobial compounds. *Saudi Pharm J* **28**, 1834–1841 (2020).

**Figures**
Figure 1

L. reuteri grows well in the microalga I. galbana. L. reuteri reaches the same concentration in I. galbana (●) and MRS (□) after 5 days of fermentation. L. reuteri: Lactobacillus reuteri; I. galbana: Isochrysis galbana; MRS: commercial medium
Figure 2

Microalgal omega3 are still available after the probiotic fermentation. Lipidomic analysis by GC-MS of *I. galbana* shows that ALA and DHA are slightly reduced, while EPA is unchanged after fermentation. ALA: alpha-linoleic acid; EPA: eicosapentaenoic acid; DHA: docosahexaenoic acid.
Figure 3

I. galbana favors the growth of L. reuteri respect to AIEC LF82. After 24 hours of growth, LF82 decreases (□) while L.reuteri increases (●) reaching the same concentration of LF82 after 5 days of fermentation.
Figure 4

The FC reduces the adhesiveness and invasiveness of AIEC LF82 to CACO2 cells. The FC significantly reduces the adhesion and invasion of LF82 compared to the probiotic and microalgae alone. AIEC: adherent invasive Escherichia coli; FC: fermented compound. */∆ P<0.05; **/∆∆ P<0.01; ***/∆∆∆ P<0.001.